晚期癌症患者心脏消耗的临床与预后意义
前瞻性纳入300例多为晚期活动性癌症但无显著心血管疾病或感染的患者,与60例健康对照和60例慢性心衰患者比较。癌症患者左室质量低于健康对照和心衰患者,低左室质量与功能状态差和全因死亡率增加相关。
要点
- 癌症患者左室质量低于健康对照和心衰患者,恶病质者最低。
- 随访中左室质量下降与每搏输出量降低和静息心率增加相关。
- 低左室质量是独立预后标志物,与功能状态差和死亡率增加相关。
核心结论
- 低左室质量与癌症患者功能状态差和全因死亡率增加相关,提供癌症心脏消耗相关心肌病的临床证据。
研究设计与样本
- 前瞻性研究纳入300例多为晚期活动性癌症但无显著心血管疾病或感染的患者,与60例健康对照和60例慢性心衰患者比较。
主要发现
- 癌症患者左室质量低于健康对照和心衰患者(177 ± 47 g vs 203 ± 64 g vs 300 ± 71 g,P < 0.001)。
- 恶病质癌症患者左室质量最低(153 ± 42 g,P < 0.001),低左室质量独立于既往心脏毒性抗癌治疗。
- 90例癌症患者二次超声心动图显示左室质量下降9.3% ± 1.4%(P < 0.001)。
- 随访中发生心脏消耗的癌症患者每搏输出量下降(P < 0.001)且静息心率增加(P = 0.001)。
- 平均随访16个月,149例死亡(1年全因死亡率43%;95% CI:37%-49%),左室质量及身高平方校正的左室质量均为独立预后标志物(均P < 0.05)。
关键数值与推荐
- 癌症患者左室质量低于预后相关切点时与整体功能状态降低和体力表现下降相关。
- 左室质量按体表面积校正掩盖了观察到的生存影响。
临床怎么用
- 对晚期癌症患者应关注左室质量评估,低左室质量提示功能状态差和预后不良。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Body wasting in patients with cancer can affect the heart. OBJECTIVES: The frequency, extent, and clinical and prognostic importance of cardiac wasting in cancer patients is unknown. METHODS: This study prospectively enrolled 300 patients with mostly advanced, active cancer but without significant cardiovascular disease or infection. These patients were compared with 60 healthy control subjects and 60 patients with chronic heart failure (ejection fraction <40%) of similar age and sex distribution. RESULTS: Cancer patients presented with lower left ventricular (LV) mass than healthy control subjects or heart failure patients (assessed by transthoracic echocardiography: 177 ± 47 g vs 203 ± 64 g vs 300 ± 71 g, respectively; P < 0.001). LV mass was lowest in cancer patients with cachexia (153 ± 42 g; P < 0.001). Importantly, the presence of low LV mass was independent of previous cardiotoxic anticancer therapy. In 90 cancer patients with a second echocardiogram after 122 ± 71 days, LV mass had declined by 9.3% ± 1.4% (P < 0.001). In cancer patients with cardiac wasting during follow-up, stroke volume decreased (P < 0.001) and resting heart rate increased over time (P = 0.001). During follow-up of on average 16 months, 149 patients died (1-year all-cause mortality 43%; 95% CI: 37%-49%). LV mass and LV mass adjusted for height squared were independent prognostic markers (both P < 0.05). Adjustment of LV mass for body surface area masked the observed survival impact. LV mass below the prognostically relevant cutpoints in cancer was associated with reduced overall functional status and lower physical performance. CONCLUSIONS: Low LV mass is associated with poor functional status and increased all-cause mortality in cancer. These findings provide clinical evidence of cardiac wasting-associated cardiomyopathy in cancer.
引用
- Lena A, Wilkenshoff U, Hadzibegovic S, et al. Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer. J Am Coll Cardiol. 2023. PMID: 37076211. doi:10.1016/j.jacc.2023.02.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。